Neurology Central

Novel aspirin formulation could target glioblastoma

Findings presented at Brain Tumours 2016 – From Biology to Therapy (27–29 June, Poland) by researchers from the Brain Tumour Research Centre of Excellence at the University of Portsmouth (UK) have revealed a potential new soluble form of aspirin which may have implications for the treatment of glioblastoma.

The University of Portsmouth group developed the reformulated aspirin, termed IP1867B, in collaboration with Innovate Pharmaceuticals (UK). The novel formulation combines aspirin with two other approved ingredients in order to create a truly soluble form of the medication, something that has yet to be achieved. Currently aspirins branded as soluble still contain small grains after dissolution that can result in the well-known gastric side-effects of the medicine.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.